Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sergliflozin Etabonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 17/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 13/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sergliflozin Etabonate SCHEMBL15827906 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL16421550 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL621808 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL18058588 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL8018797 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| Sergliflozin Etabonate SCHEMBL23731198 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1CYP3A4CYP2C19NPC1 | |
| SCHEMBL14634632 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL14634627 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL874080 | 0.96 | SLC5A2 (0.93) | SLC5A2SLC5A1NPC1RAB9A | |
| SCHEMBL4360297 | 0.92 | SLC5A2 (0.86) | SLC5A2SLC5A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4719430-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF RENAL DISEASES AND/OR HYPERTENSION IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| EP-4719429-A1 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-04-08 | — | — | EP | claimed |
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | claimed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4701626-A1 | AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION | NewAmsterdam Pharma B.V. (NL) | 2026-03-04 | — | — | EP | claimed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260014164-A1 | COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER | UNIV CORNELL (US) | 2026-01-15 | — | — | US | claimed |
| EP-4676494-A1 | SYSTEMS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S) | Boehringer Ingelheim Vetmedica GmbH (DE) | 2026-01-14 | — | — | EP | claimed |
| US-12497382-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-12-16 | — | — | US | claimed |
| WO-2022051318-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A THYROID RECEPTOR BETA AGONIST | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022051319-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A DPP-4 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220023269-A1 | Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects | BETAGENON AB (SE) | 2022-01-27 | — | — | US | claimed |
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | claimed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | claimed |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | claimed |
| US-7371730-B2 | Crystals of glucopyranosyloxybenzyl benzene derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-13 | — | — | US | claimed |
| US-20050119192-A1 | Crystals of glucopyranosyloxybenzyl benzene derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-02 | — | — | US | claimed |
| EP-1489089-A1 | CRYSTALS OF GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-12-22 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023269-A1 | Methods Of Treating Diabetes In Severe Insulin-Resistant Diabetic Subjects | GPR119, SLC5A1, SLC2A1 | SLC5A2 7/4885SLC5A1 2/4885CYP3A4 2218/4885 |
| US-20260069559-A1 | COMBINATIONS OF RXFP1 MODULATORS AND SGLT2 INHIBITORS | RXFP1, RXFP2, RXFP4 | SLC5A2 6/4885SLC5A1 5/4885CYP3A4 4079/4885 |
| US-20050119192-A1 | Crystals of glucopyranosyloxybenzyl benzene derivative | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885CYP3A4 717/4885 |
| US-20260014164-A1 | COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDER | MTOR, IRS1, IGF1R | SLC5A2 112/4885SLC5A1 81/4885CYP3A4 1377/4885 |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | FABP1, SLC2A1, SLC10A1 | SLC5A2 11/4885SLC5A1 15/4885CYP3A4 3138/4885 |
| US-12497382-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | SLC5A2 37/4885SLC5A1 27/4885CYP3A4 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.